Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK, PD and Immunogenicity of BY002 in Healthy Participants
NCT07640438Phase 1Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jun 2026
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BY002 in migraine (6 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Incidence of adverse events, injection site reactions, and serious adverse events. Started Jun 2026; status: recruiting.
02
Drugs
BY002
03
Conditions
migraine
Beyond the preview
Go deeper on NCT07640438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07640438.